^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

mitomycin

Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor
Related drugs:
10d
A novel radiosensitizer α-sulfoquinovosyl-acylpropanediol (SQAP) inhibits DNA repair pathways and sensitize cells to cancer chemotherapeutic agents. (PubMed, Sci Rep)
SQAP sensitized series of chemotherapeutic agents including doxorubicin, carboplatin, bleomycin, camptothecin, etoposide, methyl methanesulfonate, cisplatin, mitomycin C, and Taxol in canine tumor cells and V79 cells. These results suggest that broad inhibition of DNA repair may play a role in SQAP induced radiosensitization and chemosensitization.
Journal
|
RAD51D (RAD51 paralog D) • XRCC1 (X-Ray Repair Cross Complementing 1)
|
cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride • etoposide IV • mitomycin • bleomycin
14d
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report. (PubMed, Cancer Chemother Pharmacol)
This case report supports the clinical utility of pre-emptive DPYD genotyping to guide initial 5-FU dosing in intermediate metabolizers, and it suggests that all patients still require close monitoring and some (particularly carriers of c.2846 A > T) may require an initial dose reduction greater than the recommended 50% to prevent severe toxicity.
Journal
|
DPYD (Dihydropyrimidine Dehydrogenase)
|
5-fluorouracil • capecitabine • mitomycin
22d
P2 data • Journal
|
BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 mutation • TP53 wild-type
|
mitomycin
24d
MoonRISe-3: A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
P3, N=220, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2027 --> Apr 2028
Trial primary completion date
|
gemcitabine • mitomycin • erdafitinib intravesical delivery system (TAR-210)
1m
A porcine model of Fanconi anemia. (PubMed, PLoS One)
In addition, FANCA disruption followed by mitomycin C treatment resulted in a > 10-fold increase in chromosomal radials, a finding that is considered diagnostic for human FA...Targeting of FANCD2 failed to produce any biallelic animals demonstrating the loss of FANCD2 function is embryonic lethal in pigs. These results indicate that a porcine model of FANCA holds promise for the development of strategies to prevent the development of bone marrow failure and malignancies in patients with FA.
Preclinical • Journal
|
FANCA (FA Complementation Group A) • FANCD2 (FA Complementation Group D2)
|
mitomycin
1m
Trial completion
|
AFP (Alpha-fetoprotein)
|
cisplatin • mitomycin
1m
Diversity of oxidative stress and senescence phenotypes induced by chemotherapeutic agents in HUVECs. (PubMed, Sci Rep)
HUVECs were treated with DNA crosslinkers (doxorubicin, mitomycin C), topoisomerase inhibitors (etoposide, camptothecin), and methotrexate (MTX)...ROS scavenger Mito-Q and ATM inhibitor KU55933 were co-administered to evaluate their modulatory effects...Chemotherapeutic agents triggered endothelial senescence via DNA damage and ROS accumulation, with heterogeneity in potency and mechanisms. ROS scavengers may mitigate methotrexate-associated vascular toxicity, and targeting ROS could enhance chemotherapy safety by preserving endothelial function.
Journal
|
TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
doxorubicin hydrochloride • etoposide IV • methotrexate • mitomycin • KU-55933
2ms
Enrollment closed
|
mitomycin • Inlexzo (gemcitabine intravesical system)
2ms
Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management. (PubMed, Oncol Res)
The most employed topical agents include mitomycin C (MMC), 5-fluorouracil (5-FU), and interferon alpha-2b (IFNα2b), each with distinct mechanisms of action, efficacy profiles, and toxicity risks. Timely recognition and management of complications are essential to minimize long-term sequelae. Reliance on compounded formulations highlights the need for stable, standardized, and commercially available topical agents specifically designed for ocular use to ensure safety, reproducibility, and global accessibility.
Review • Journal • Adverse events
|
IFNA1 (Interferon Alpha 1)
|
5-fluorouracil • mitomycin
2ms
Influence of the Chemotherapeutic Agent Mitomycin C on In Vitro Dendritic Cell Maturation and Interleukin-12 Production in a Colorectal Cancer Model. (PubMed, Iran J Immunol)
While increasing the Mitomycin C dose to 80 nM further upregulated HLA-DR and CD86 expression, the release of IL-12 was highest a 50 nM concentration of mitomycin C (686.7 ± 125.7 pg/mL compared to 263.8 ± 4.8 pg/mL in controls; p < 0.05). IL-12 levels were not significantly increased even with 30 nM Mitomycin C. Low concentrations of Mitomycin C contributed to an increase in dendritic cellmaturation and an increase in the expression of co-stimulatory molecules (CD80, CD86, CD83, and HLA-DR), along with the secretion of cytokines such as IL-12p70, IL-2, and GM-CSF.
Preclinical • Journal
|
IL2 (Interleukin 2) • CD14 (CD14 Molecule) • CSF2 (Colony stimulating factor 2) • IL4 (Interleukin 4) • ITGAX (Integrin Subunit Alpha X) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
mitomycin
2ms
RNF4 and USP7 coordinate spatial regulation of SLX4 stability within the PML nuclear bodies. (PubMed, Nucleic Acids Res)
One key regulator of nuclease activity is the scaffold protein SLX4, which plays important roles in repairing DNA damage induced by mitomycin C (MMC) and camptothecin (CPT) as well as in the resolution of stalled replication forks...These findings suggest that SLX4 and its associate nucleases are confined within PML NBs and that the optimal protein level of SLX4 is maintained by the coordinated activities of RNF4 and USP7. Our findings provide insight into how cells effectively control the potentially harmful activities of nucleases in the absence of DNA damage by a spatial regulatory mechanism.
Journal
|
MUS81 (MUS81 Structure-Specific Endonuclease Subunit) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit) • USP7 (Ubiquitin Specific Peptidase 7)
|
mitomycin
2ms
Conjunctival Melanoma: Current Management. (PubMed, Int Ophthalmol Clin)
Topical mitomycin-C eye drops are used for diffuse flat melanoma or PAM with severe atypia...Risk factors for metastasis include: greater tumor thickness, non-bulbar location, low tumor pigmentation, histologic ulceration, >1 mitotic figure per mm2, and adjacent structures invasion. Localized tumors should be excised en block, and incisional biopsy should be avoided, which could lead to local widespread tumor dissemination and subsequent recurrence and metastasis.
Review • Journal • IO biomarker
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)
|
BRAF V600E • BRAF V600
|
mitomycin